Prostate cancer-specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial priorities.
Edward Christopher DeeMichelle D NezoloskyFallon E ChipidzaMelaku A AregaSantino S ButlerSybil T ShaBrandon A MahalPaul L NguyenDavid D YangVinayak MuralidharPublished in: The Prostate (2020)
Although high-risk and very high-risk disease account for one-fifth of diagnoses, they account for two-thirds of 10-year PCSM. Older patients and black patients with low-risk disease accounted for a disproportionately large proportion of deaths. These findings support targeting research toward high-risk disease and ensuring adequate representation of older and black men in clinical trials.